Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Support

This activity is supported by an educational grant from Genentech, member of the Roche Group.

Medical Crossfire®: Expert Perspectives in Sustained Delivery of Anti-VEGF Therapies – Understanding How Novel Treatments May Shift the Paradigm

Release Date: August 31, 2021
Expiration Date: August 31, 2022

Activity Overview

Medical Crossfire™, one of PER’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirted discussions about a clinical topic. In this activity, four thought leaders explore the emerging data surrounding sustained-delivery anti-vascular endothelial growth factor (Anti-VEGF) therapies for the management of neovascular retinal diseases like neovascular age-related macular degeneration (nAMD). This lively debate will place new developments into clinical context to help you optimize care for patients with neovascular retinal diseases.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Genentech, member of the Roche Group.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This online educational activity is directed toward ophthalmologists and retinal specialists. Other health care professionals involved in the treatment of patients with nAMD are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss the unmet clinical needs for durable, sustained treatment options for patients with AMD
  • Analyze the efficacy and safety data for novel sustained delivery options of anti-VEGF therapies for the treatment of AMD
  • Incorporate novel sustained delivery options of anti-VEGF therapies into management plans for patients with AMD

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Arshad M. Khanani, MD, MA
Arshad M. Khanani, MD, MA
Clinical Associate Professor
University of Nevada, Reno School of Medicine
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Reno, NV

Disclosures: Grant/Research Support: Genentech, Inc.; Adverum Biotechnologies; Regenxbio Inc.; Consultant: Genentech, Adverum Biotechnologies; Regenxbio Inc.; Speaker’s Bureau: Genentech Inc.


Sophie J. Bakri, MD
Sophie J. Bakri, MD
Chair, Department of Ophthalmology
Mayo Clinic
Rochester, MN

Disclosures: Consultant: Adverum Biotechnologies; Allergan plc; Alimera Sciences Inc.; Apellis Pharmaceuticals; Kala Pharmaceuticals Inc; Novartis, Outlook Therapeutics, Inc.; F. Hoffmann-La Roche AG; Regenexbio Inc.; Re-Vana Therapeutics Ltd; Zeiss Pharma Ltd.

Peter K Kaiser, MD
Peter K Kaiser, MD
Professor of Ophthalmology
Chaney Family Endowed Chair in Ophthalmology Research
Cleveland Clinic Lerner College of Medicine
Cole Eye Institute
Cleveland, OH

Disclosures: Consultant: Allergan plc, Kanghong Pharmaceutical, Regeneron Pharmaceuticals, Bayer Corporation, Novartis Pharmaceuticals, Kodiak Sciences.

Carl D. Regillo, MD
Carl D. Regillo, MD
Professor of Ophthalmology
Thomas Jefferson University
Chief, Retina Service
WillsEye Hospital
Philadelphia, PA

Disclosures: Grant/Research Support: Adverum Biotechnologies; Allergan plc; Annexon Biosciences; Astellas Pharma Inc.; Chengdu Kanghong Pharma; EyePoint Pharmaceuticals, Inc.; Graybug Vision; Iveric Bio; Kodiak Sciences Inc.; Lineage Cell Therapeutics; NGM Biopharmaceuticals Inc.; Notal Vision; Novartis Pharmaceuticals; Opthea Ltd; Regeneron Pharmaceuticals; RegenXBio Inc.; Consultant: Adverum Biotechnologies; Alderya Therapeutics, Allergan plc; Annexon Biosciences; Aviceda Therapeutics; Chengdu Kanghong Pharma; Eyepoint Pharmaceuticals, Inc.; Genentech, Inc.; Graybug Vision; Iveric Bio; Kodiak Sciences Inc.; Lineage Cell Therapeutics; Merck & Co.; NGM Biopharmaceuticals Inc.; Notal Vision; Novartis Pharmaceuticals; Ocugen, Inc.; Opthea Ltd; Stealth BioTherapeutics; Takeda Pharmaceutical Company Limited ; Théa Pharmaceuticals Limited; Zeiss Pharma Ltd.; Stock/Shareholder: Iveric Bio.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By